innoscripta Stock Jumps 17% to EUR 48.20 as Management Breaks Silence on Tax Probe

innoscripta stock climbs 17% to EUR 48.20 after hitting a 52-week low of EUR 31.05 amid a tax investigation into research grant benefits.

Shares of innoscripta staged a sharp rebound on Friday, climbing 17% to EUR 48.20, as the software company moved to reassure investors rattled by a tax investigation that had driven the stock to a fresh 52-week low of EUR 31.05 in recent sessions. The advance, which follows a bruising sell-off, came without any fresh corporate catalyst, with media reports attributing the move to a technical counter-reaction and a first dose of calm from the leadership team.

The turbulence traces back to raids carried out at innoscripta's sites in Tutzing and Munich. Prosecutors are examining suspicions that the company aided clients in obtaining unjustified tax benefits tied to research grants. The shock of those measures initially sent the stock into a tailspin, and Friday's rally represents the market's first attempt to find its footing since.

A Question of Scope

At the heart of the next leg for the share price is how far the allegations reach. Whether the accusations remain isolated incidents from years past, or instead point to a broader problem across the business model, will determine whether the capital market regains its confidence. Should the suspicion widen to the entire operation, a re-rating of risk would loom.

According to the company, the matters described relate — on the basis of preliminary findings — to possible misconduct by individual employees. Management stressed that one staff member connected to the case has not been with the firm for several years. On the company's own account, business transactions in the current financial year are not affected by the investigation.

At the same time, innoscripta conceded that a definitive assessment of the financial or other consequences is not yet possible. That residual uncertainty sits at the core of the current unease: until investigators wrap up their review, an unquantifiable risk remains on the table.

Operations in the Spotlight

The company has been keen to redirect attention to its underlying performance. In an interview on 28 September, CFO Alexander Meyer and COO Sebastian Schwertlein walked through the operational story, international growth and the expansion of the firm's systems. For the first six months of 2026, innoscripta posted revenue growth of 43%, while earnings before interest and taxes rose 49% over the same period. The two executives also highlighted the software company's international progress.

Management has likewise pointed to an expansion into Austria and the research premium available there. Innoscripta says it is cooperating fully with the authorities and that regular business operations continue without restriction.

Two Paths Ahead

A swift and transparent resolution would ease the legal overhang considerably. If the company's account holds — misconduct by former employees, with the current business untouched — the pressure should fade, letting investors refocus on operating prospects. In an optimistic reading, shareholders would take the episode as evidence of long-term backing from strategic investors, clearing the way for a fundamental re-evaluation.

The opposing scenario is darker. Tax-criminal investigations routinely drag on for many months. Such a stretch of uncertainty ties up management capacity and weighs on the company's reputation with prospective new clients. If customers grow more hesitant about applying for research grants, future new business could suffer. The scale of any financial burdens or back-payments cannot currently be quantified, and lingering doubt over the outcome could keep institutional investors at arm's length for good. Should the authorities' review surface additional points of concern, Friday's rebound could quickly unravel, opening the door to a slide back toward the EUR 31.05 low.

A Date With Shareholders

For traders, the path forward hinges on a simple line in the sand: as long as the stock defends its recent recovery and no new allegations emerge, there is room to climb. If confidence cracks again — through fresh regulatory steps or charges touching the current financial year — the shares face a renewed downward move.

The next concrete catalyst is a direct sit-down with owners. Innoscripta has invited shareholders to a product presentation at its Tutzing headquarters, with exact dates to be announced at short notice. The event hands management a chance to demonstrate transparency and put its own software offerings front and centre — a platform that could prove decisive in shaping what comes next for the stock.